

Case report

Post Covid Cardiac Crisis: A Clinical Case Report

Zannat K¹, Akhiruzzaman², Nasreen T³, Choudhury SA⁴

Abstract:

Millions of people were infected during the last Covid pandemic and imposed a long term effect to the survivors. The incidence of post-COVID syndrome is estimated at 10–35%, while for hospitalized patients it may reach 85% among them nearly one-fourth have been diagnosed with cardiovascular complications. This case report is discussing about a 32 years old young man who went to Japan for higher education but came back during covid pandemic and developed fever, cough, respiratory distress and hemoptysis with which he was admitted to Covid ward at Shahid Ziaur Rahman Medical College Hospital (SZMCH). Relevant investigations revealed that he was Covid positive along with pneumonia (>50% lung involvement) and Hypertension. After one week, when his condition was stable he was discharged from hospital and advised for home quarantine for 14 days. But within 7 days of discharge, he again developed cough with hemoptysis, unusual fatigue, chest tightness and restlessness. That time he consulted with a cardiologist and physician found bilateral pneumonia along with dilated cardiomyopathy with Ejection Fraction 31%. After this devastating condition he was referred to Dhaka for better management and during follow-up we found his EF was 53% which was far better than the initial stage. Due to some rapid and prompt actions he survived but living with restricted activities.

Key Words: Covid-19, Post Covid Crisis, Complication, Cardiomyopathy.

Introduction

The First recorded Pandemic of world history happened in between 6th to 8th century (plague of Justinian) and then during 14th to early 19th century, 2nd plague pandemic (Black Death) took millions of life. Afterwards world experienced cholera, HIV/AIDS, different flu such as Swine flu, Russian flu, Asian flu, Spanish flu, MARS, SARS, appeared in the form of pandemic & epidemic worldwide.¹

The severe acute respiratory syndrome Corona virus-2 (SARS-CoV-2) or Corona virus disease 2019 (COVID-19) initially surfaced in December 2019 from Wuhan, China, sweeping the world with various strains, forcing the WHO to declare a pandemic in March 2020. Shortly afterward, the virus spread rapidly across the world, (ultimately among 133 countries) sparking a global pandemic affecting hundreds of millions of people with millions of deaths worldwide.² COVID-19 can cause a wide range of clinical manifestations by affecting multiple systems.

COVID-19 manifests with a wide array of presentations, which ranges from fever, fatigue, and diarrhoea to severe respiratory and cardiovascular complications and multiple organ failure leading to mortality.³

Post-COVID syndrome was described in the spring of 2020 after the earliest COVID-19 cases were reported; observations declared that COVID-19 patients had symptoms that remained for several weeks or months after infection. The long-term complications of COVID are well known as post covid syndrome.⁴

Post-COVID-19 syndrome is poorly understood as it affects COVID19 survivors at all levels of disease severity and across all age ranges. The disease is most associated with post-discharge dyspnea and fatigue. However, other persistent symptoms as chest pains, palpitations, myalgia, smell and taste dysfunctions, cough, headache, gastrointestinal and cardiac-related problems.^{5,6}

Author's Affiliation:

1. *Kutbul Zannat, Senior Lecturer, Department of Community Medicine & Public Health, TMSS Medical College, Bogura.
2. Akhiruzzaman, Associate Professor, Department of Community Medicine & Public Health, TMSS Medical College, Bogura.
3. Tahsina Nasreen, Assistant Professor, Department of Community Medicine & Public Health, TMSS Medical College, Bogura.
4. Shamim Ahmed Choudhury, Associate Professor & Head, Department of Community Medicine & Public Health, TMSS Medical College, Bogura

Address of Correspondence : *Kutbul Zannat, Senior Lecturer, Department of Community Medicine & Public Health, TMSS Medical College, Bogura.

In this report, we discuss cardiac complication of post covid19 condition so that the most important outcomes and clinical practice is use to compare and collate the findings with clinical recommendations for patients care.

Case Report:

A 32 years old young man, from Uzgram, Gabtoli, Bogura went to Japan (Shimani) for higher education on agriculture in 2016, October. Besides that he took part-time job for Weekly 22 hours. Due to excessive work load with Lab works he faced sleep disturbance and different types of physical discomfort which ultimately diagnosed as high blood pressure and advised for changing dietary habit and sleep pattern by Japanese doctors. But there was no significant improvement. Then he stated anti hypertensive drugs advised by the local Doctor at Shimane, Japan and continued for two to three months. He had no previous history of hypertension but got family history. In April 2019 when he was working as a post doc. research assistant, at Japan Global Infrastructure Research Foundation, again suffered from raised blood pressure and suggested to modify lifestyle by university health center. During Covid pandemic situation he came Bangladesh on September, 2020. On June, 2021 his brother was diagnosed as a case of covid-19. During that time he had to take care of him which even needs to be close association without any protective measures. After 2-3 days he developed fever which was increasing day by day associated with cough & respiratory distress. Cough was gradually aggravated and hemoptysis started along with fever. He went to Shahid Ziaur Rahman Medical College Hospital Bogura (SZMCH) and due to covid pandemic situation, doctor advised him to get admitted into covid ward. Here he was diagnosed as covid positive by relevant investigation. With other investigations HRCT (Chest) was done and found "Covid-19 related pneumonia" where lung involvement was >50% & O₂ Saturation was 52%. Test like SGPT, RBS, S. creatinine, D-dimer, Ferritin, S.LDH, Hematology analysis, S. electrolytes, CRP all were done and found within normal range. He was discharged after 1 week of admission with advice of Tab. Amlodipine 5 mg, Tab. Doxofylline 200 mg, Tab. Montelukast, Tab. Levocetirizine Dihydrochloride with advice of maintaining home quarantine. After 7 days of leaving hospital, he again developed cough with hemoptysis, unusual fatigue, chest tightness and restlessness. Then he went to a medicine specialist for further treatment on 1st August 2021. He was advised for some investigations like, sputum for AFB, Echocardiography (colour doppler), Chest X-ray and ECG. X-ray chest revealed mild Cardiomegaly with bilateral pneumonia, and echocardiography found dilated cardiomyopathy with EF 31% only. Then he was referred to SZMCH cardiology unit and admitted there for five days (from 14.8.2021 to 18.8.2021) and diagnosed as DCM with post covid status and managed with Tab. Spironolactone (20/50), Tab. Atorvastatin (20 mg), Tab. Aspirin (75mg), Tab. Valsartan (50mg), Tab.

Ivabradine (5mg), Tab. Trimetazidine (35mg), Tab. Montelukast (10 mg) Tab. Esomeprazole. His condition was not improving as For further management he went to a medicine and cardiology specialist at Dhaka. Now his EF is 53% & he is feeling better with medication of Tab. Valsartan (100mg), Tab. Carvedilol (6.25mg), Tab. Eplerenone (25mg), Tab. Empagliflozin (10 mg), Tab. Fenofibrate (200 mg). He is stable but he could not complete his PhD course at Japan because his movement is restricted and now he is working as a sales man in a medicine shop at Bangladesh.

ECHOCARDIOGRAPHY									
ID No.	BG164463					Date: Fri 13/08/21			
Patient's Name	MR. MORSHED ALOM					Age: 28 Year(s) Sex: Male			
Refd. By									
Specimen	Echo Colour Doppler								
M-MOOD & 2D MEASUREMENTS:									
AO	32 mm	LVIDd	80 mm	IVSd	09 mm	MVA	Cm ²		
LA	49 mm	LVIDs	66 mm	PVd	08 mm	MV annulus	mm		
ACS	13mm	FS	15 %	MPA	mm	AV (ring)	mm		
RVIDd	43mm	EF	31 %	MV (EPSS)	mm	TAPSE	14mm		
Doppler & Colour Flow Study:									
	Peak Velocity	Peak PG	Mean PG	MR	Value	Value			
MV	1.0 (m/sec)	4.8 (mmHg)	(mmHg)	AR	trace	A (m/sec)			
AV	1.0 (m/sec)	4.8 (mmHg)	(mmHg)	PR		E/A ratio	2.24		
PV	0.7 (m/sec)	2.3 (mmHg)	(mmHg)	TR	mild	OT (sec)			
TV	(m/sec)	(mmHg)	(mmHg)	AVA (cm ²)		PH (sec)			
TR	(m/sec)	(mmHg)	(mmHg)	PASP (mmHg)	52	MVA (cm ²)			
				PAOP (mmHg)		AVA (cm ²)			
				OP QS		E/E'	24		
DESCRIPTION									
Chambers	All the chambers are dilated. No intracardiac clot & mass is seen.								
LV wall motion	Global hypokinesia.								
Pericardium	No pericardial effusion is seen.								
Valves	MV: Non coaptation. Other valves are normal in morphology.								
IAS & IVS	Intact.								
Great vessels	Normal.								
Colour Flow	MR severe, TR mild, AR trace.								
Conclusion:	1. Dilated cardiomyopathy. 2. Moderate LV systolic dysfunction. 3. Severe LV diastolic dysfunction. 4. Mild RV systolic dysfunction. 5. Moderate pulmonary hypertension. 6. MR severe. 7. Mild TR. 8. AR trace.								

X-Ray Report	
ID No.	BG153433
Patient's Name	MR. MORSHED ALOM
Refd. By	
Specimen	Digital X-Ray of Chest PA view
Date: Sun 01/08/21	
Age: 28 Year(s) Sex: Male	
CHEST PA VIEW	
Trachea	Central in position.
Lung	Non homogeneous opacities are seen in both lower zones.
Hilar Shadows	Normal. X-ray Chest (P/A view)
Heart	Mildly enlarged in transverse diameter.
Costophrenic angles	Clear.
Diaphragm	Normal in level and contour.
Bony Thorax	Normal.
IMPRESSION:	1. Cardiomegaly (Mild). 2. Pneumonia (Bilateral). Please correlate clinically.

Echocardiography Report	
Department of Cardiology	
Shaheed Ziaur Rahman Medical College Hospital, Bogura, Bangladesh	
Date: 22.06.2021	Echo No. 1
Name: Mr. Morshed Alam	Age: 32
Sex: M	Year/Month/Day
Clinical Diagnosis:	
Procedures: <input checked="" type="checkbox"/> M-mode <input checked="" type="checkbox"/> 2D <input type="checkbox"/> Doppler <input type="checkbox"/> CFI <input type="checkbox"/> TTE <input type="checkbox"/> TTE <input type="checkbox"/> Stress Echo	
M-Mode & 2D findings:	
AO: 30 mm	LVIDd: 63 mm
LA: 31 mm	LVIDs: 45 mm
IVsd: 17 mm	FS: 48 %
LVPWd: 11 mm	EF: 56 %
Doppler & Colour Flow measurements:	
MV Vp: m/sec	PPG: mmHg
AV Vp: m/sec	PPG: mmHg
PV Vp: m/sec	PPG: mmHg
TV Vp: m/sec	PPG: mmHg
Description:	
Chambers:	
LA:	<input type="checkbox"/> Normal <input type="checkbox"/> Dilated <input type="checkbox"/> Appendage: clear/hazy
LV:	<input type="checkbox"/> Normal <input type="checkbox"/> Dilated <input type="checkbox"/> Small <input type="checkbox"/> Concentric/Eccentric hypertrophy-present
RA:	<input type="checkbox"/> Normal <input type="checkbox"/> Dilated <input type="checkbox"/> Small <input type="checkbox"/> Conc. hypertrophy-present
RV:	<input type="checkbox"/> Normal <input type="checkbox"/> Dilated <input type="checkbox"/> Small <input type="checkbox"/> Conc. hypertrophy-present
VALVES:	
MV:	<input type="checkbox"/> Normal <input type="checkbox"/> AML/PML-Thickened <input type="checkbox"/> Calcification-present <input type="checkbox"/> Diastolic doming of AML
AV:	<input type="checkbox"/> Non-coaptation-present <input type="checkbox"/> Commissures-Medial-free/fused <input type="checkbox"/> Lateral-free/fused
PV:	<input type="checkbox"/> Normal <input type="checkbox"/> Dilated <input type="checkbox"/> Thickened <input type="checkbox"/> Movement suggestive of pulmonary hypertension <input type="checkbox"/> Doming-Present
TV:	<input type="checkbox"/> Normal <input type="checkbox"/> Dilated <input type="checkbox"/> Thickened <input type="checkbox"/> Non-coaptation-present <input type="checkbox"/> Doming-Present
AS:	<input type="checkbox"/> Intact <input type="checkbox"/> Defect-Primus/Secundum/Sinus Venosus
PS:	<input type="checkbox"/> Intact <input type="checkbox"/> Defect-Primus/Secundum/Sinus Venosus
PERICARDIUM:	<input type="checkbox"/> Normal <input type="checkbox"/> Thick <input type="checkbox"/> Calcification-Present <input type="checkbox"/> Effusion: Absent/Present-Mild/Moderate/Severe
THROMBUS/VEGETATION/OTHER MASS: <input type="checkbox"/> Not Seen <input type="checkbox"/> Seen in or on	
Impression:	
Anterior wall hypokinesis	
Fair LV systolic function (EF-56%)	
Mild MR	
CONSULTANT CARDIOLOGIST	

ID No.	202	Date	06.07.2021	Sex	Male
Patient's name	Morshed Alam	Age	29 Yrs.		
Refd by					
HISTORY:					
Male aged 29 yrs. With H/O Covid -19 pneumonia.					
TECHNIQUE:					
2 mm thickness axial interval non contrast spiral scans with 0.6 mm coronal, sagittal reconstruction images were done.					
FINDINGS:					
Scattered areas of ground glass opacities are noted at different lung segments of both sides, predominantly peripheral in distribution.					
The heart & mediastinum is centered.					
Pulmonary vasculature appears normal.					
Both the hila are normal in density. No hilar, paratracheal or mediastinal lymphadenopathy detected.					
Thoracic walls are normal. No erosion of vertebral body or rib is seen.					
Visualized part of liver appears normal.					
CONCLUSION: Covid -19 pneumonia (Lung involvement is more than 50%).					



(N.B: All reports kept as record and name of the reporting doctors and institutions are blurred)

Discussion:

COVID-19 has been found to cause heart damage and consequently a number of heart problems, including cardiomyopathy (CMPs), even after people recover from COVID-19. Nearly one-fourth of those hospitalized with COVID-19 have been diagnosed with cardiovascular complications, which have contributed to roughly 40% of all COVID-19-related deaths.⁷

Before the pandemic, about 1% to 2% of acute coronary syndrome cases were attributed to stress-induced cardiomyopathy. During the pandemic, this number rose to about 8%. Some of these cases were traced to the havoc that the virus wreaks inside the body, but a large number developed in people who had tested negative for COVID-19.⁸ Even a mild case of COVID-19 can lead to long-term, sometimes permanent, heart damage.⁹

COVID-19 has resulted in other organ involvement, and CMPs are among the most significant complications of this rapidly emerging disease, causing more severe disease and increased mortality rates^{10,11} The patient's recovery and death rates were assessed in 20 studies that showed that 28.7% of patient's with one type of CMPs died following SARS-CoV-2 infection. Patients with cardiovascular co- morbidities had a higher risk of developing cardiac injury.¹²

In a systematic review study, hypertension was the most common underlying condition in CMPs following COVID-19, reported in 33% of patients.¹³

A study of >150,000 US veterans found that individuals with COVID-19 are at increased risk of cardiovascular disease including myocarditis beyond 30 days post-infection, even those who were not hospitalized during active infection.¹⁴ Cardiac involvement of COVID-19 infection is an important clinical consequence to recognize. One study reported cardiac magnetic resonance imaging (MRI)-proven myocardial inflammation in 60% of patients who had recently recovered from COVID.¹⁵ Another study showed that 7%-20% of patients with COVID-19 had elevated cardiac biomarkers or electrocardiogram (ECG) abnormalities indicating underlying myocardial injury or ischemia [16]. Another study showed that up to 20%-30% of patients hospitalized with COVID-19 has evidence of myocardial involvement.¹⁷

In conclusion, cardiac injury and CMPs, including exacerbation of an underlying CMPs or the emergence of new CMPs, are common in COVID-19 patients. Moreover, they are associated with higher mortality and morbidity in these patients. Common fatal conditions in patients with COVID19 CMPs include multiorgan damage, ARDS, and cardiogenic shock. Therefore, diagnostic measures of COVID-19 should consist of underlying cardiovascular comorbidities.

Conclusion

The emergence of post-COVID 19 cardiovascular manifestations is expected to impose a further detrimental effect on the incidence, prevalence, and economic projections of heart disease. Limited elucidation of its clinical course has prompted the requirement to ascertain the persistent symptoms and clinical outcomes. History, signs, and symptoms of cardiac injury should be considered in evaluating these patients early in the course of this novel disease, and prompt therapeutic measures for the prevention of exacerbating cardiac condition should be sought.

References

1. Whitfield, J. (2002). "Portrait of a serial killer". *Nature*. doi:10.1038/news021001-6.
2. S. Shi, M.u. Qin, B.o. Shen, Y. Cai, T. Liu, F. Yang, W. Gong, X.u. Liu, J. Liang, Q.
3. Zhao, H.e. Huang, B.o. Yang, C. Huang, Association of Cardiac Injury with Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiol.* 5 (7) (2020) 802, <https://doi.org/10.1001/jamacardio.2020.0950>.
4. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol.* 2021;19(3):141-154.
5. Liu JWTW, De Luca R, Mello Neto HO, Barcellos I. Post-COVID-19 Syndrome? New daily persistent headache in the aftermath of COVID-19. *ArqNeuropsiquiatr.* 2020;78:753-4.
6. S. Shaobo, M. Qin, Y. Cai, T. Liu, B. Shen, F. Yang, S. Cao, Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019, *Eur. Heart J.* 41 (2020) 2070–2079.
7. Shah, W.; Hillman, T.; Playford, E.D.; Hishmeh, L. Managing the long term effects of COVID-19: Summary of NICE, SIGN, and RCGP rapid guideline. *BMJ* 2021, 372, n136.
8. American Heart Association. What COVID-19 is doing to the heart, even after recovery.
9. Kir D, Beer N, De Marchena EJ. Takotsubo cardiomyopathy caused by emotional stressors in the coronavirus disease 2019 (COVID-19) pandemic era. *J Card Surg.* 2021;36(2):764-769. doi:10.1111/jocs.15251
10. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. *Nat Med.* 2022;28(3):583-590. doi:10.1038/s41591-022-01689-3
11. Bonow RO, Fonarow GC, O’Gara PT, Yancy CW. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. *JAMA Cardiol.* (2020) 5:751–3. 10.1001/jamacardio.2020.1105 [PubMed] [CrossRef] [Google Scholar]
12. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol.* (2020) 17:259–60. 10.1038/s41569-020-0360-5 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* (2020) 395:1054–62. 10.1016/S0140-6736(20)30566-3 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
14. Sawalha K, Abozenah M, Kadado AJ, Battisha A, Al-Akchar M, Salerno C, et al.. Systematic review of COVID-19 related myocarditis: Insights on management and outcome. *Cardiovasc Revasculariz Med.* (2020) 23:107–13. 10.1016/j.carrev.2020.08.028 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
15. Long-term cardiovascular outcomes of COVID-19. Xie Y, Xu E, Bowe B, Al-Aly Z. *Nat Med.* 2022;28:583–590. [PMC free article] [PubMed] [Google Scholar]
16. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from Coronavirus Disease 2019 (COVID-19) Puntmann VO, Carerj ML, Wieters I, et al. *JAMA Cardiol.* 2020;5:1265–1273. [PMC free article] [PubMed] [Google Scholar]
17. Basu-Ray I, Almaddah NK, Adeboye A, Soos MP. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2023. Cardiac manifestations of coronavirus (COVID-19) [PubMed] [Google Scholar]
18. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. Mitrani RD, Dabas N, Goldberger JJ. *Heart Rhythm.* 2020;17:1984–1990. [PMC free article] [PubMed] [Google Scholar]